Healthia (ASX:HLA) - CEO, Wesley Coote
CEO, Wesley Coote
Source: Healthia
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Healthia (HLA) shares enjoyed a 10 per cent rise after reporting a $1.62 million acquisition of Queensland’s Rothwell Physiotherapy
  • The ASX-lister estimates the family-owned physiotherapy business could bring in $2.13 million in additional revenue
  • Healthia will pay $1.3 million as upfront consideration and expects to complete the buy before the end of November
  • Healthia shares were up 10.3 per cent to trade at $1.99 at 1:52 pm AEST

Healthia (HLA) shares have enjoyed a 10 per cent rise after reporting a $1.62 million acquisition of Queensland’s Rothwell Physiotherapy.

The ASX-lister announced to the market it had entered a binding agreement to acquire the family-owned and operated physiotherapy business, which provides physiotherapy and exercise physiology to adults and children.

The acquisition is tipped to bring in $2.13 million in additional revenue and contribute $0.36 million to earnings before interest, taxes, depreciation and amortisation (EBITDA).

Healthia will pay $1.3 million as upfront consideration for the business, including $0.32 million in clinic class shares.

It is expected the acquisition will be completed on or before November 30 2021, subject to property leases and customary conditions.

Healthia Managing Director Wesley Coote said the company was looking forward to bringing Rothwell Physiotherapy into the group.

“The addition of Rothwell Physiotherapy is in line with Healthia’s stated growth strategy and brings us one step closer to being the number one provider of physiotherapy services in Australia,” he said.

“We have a strong acquisition pipeline in place for this financial year underpinned by industry participants placing greater value on the support and stability that a larger group such as Healthia, can provide.”

Healthia shares were up 10.3 per cent to trade at $1.99 at 1:52 pm AEST.

HLA by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…